[1]中华医学会.病毒性肝炎防治方案[J].中华传染病杂志, 2001, 19 (11) ∶56-62.
|
[2]中华医学会.慢性乙型肝炎防治指南[J].中华传染病杂志, 2005, 23 (6) ∶421-431.
|
[3]饶日春, 郑瑞丹, 张闽峰, 等.666例肝穿活体组织检查病理分析[J].实用肝脏病杂志, 2004, 7 (2) ∶101-102.
|
[4]陆张兵, 邵茜雯.病毒性肝炎患者临终前临床与病理诊断对照分析[J].南京铁道医学院学报, 2001, 20 (1) ∶44-46.
|
[5]于晓辉, 赵连三, 张秀辉, 等.慢性乙型肝炎临床与病理的一致性[J].胃肠病学和肝病学杂志, 2005, 14∶71-73.
|
[6]顾生望, 章廉, 冯筱格, 等.1023例病毒性肝炎临床与病理诊断分析[J].临床肝胆病杂志, 2001, 17 (1) ∶41-42.
|
[7]王宇明, 陈耀凯.肝衰/重型肝炎的研究进展[J].临床内科杂志, 2002, 19 (4) ∶247~250.
|
[1] | Yu ZHANG, Yongfeng YANG. Thinking of the pathological diagnosis of unexplained liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(3): 498-503. doi: 10.3969/j.issn.1001-5256.2023.03.003 |
[2] | Society for Hepatobiliary, Medical Society of Western Retuned Scholars Association, Society for Molecular Diagnosis, Chinese Research Hospital Association, SMD/CRHA, Expert Committee for Liver Cancer, Chinese Society of Clinical oncology, Professional Committee for the Prevention and Control of Hepatobiliary and Pancreatic Diseases, Chinese Preventive Medicine Association, Expert Committee for Liver Cancer, Asia Pacific Alliance of Liver Diseases. Consensus for clinical application of molecular diagnosis on hepatobiliary carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1482-1488. doi: 10.3969/j.issn.1001-5256.2020.07.008 |
[3] | Zhang DongSheng, Zhang JingJing, Wang PingFan, Qiu Na. The Specific Expression and Pathological Diagnostic Value of Survivin in Gallbladder Adenoma[J]. Journal of Clinical Hepatology, 2010, 26(1): 44-46. |
[4] | Zhang XueSong, Jin Rui, Ding HuiGuo, Guo XinHui, Liu Zhuang, Zhao Min, Li HanWei. The efficacy of lipo pgel in treating chronic severe hepatitis[J]. Journal of Clinical Hepatology, 2008, 24(5): 341-343. |
[5] | Lu: Chao, Lu Jian, Xin HaiGuang, Wang JunXue. Logistic regression analysis of multiple factor that may influence the prognosis of chronic hepatic failure[J]. Journal of Clinical Hepatology, 2008, 24(6): 428-431. |
[6] | Zhan LingLing, Lu: XiaoPing, Li Shan, Jiang HaiXing. Relationship between the prognosis of chronic severe hepatitis and the expression of urokinase-type plasminogen activator[J]. Journal of Clinical Hepatology, 2007, 23(3): 170-171. |
[11] | Chen Lin. Effects of lipid microspheres prostaglandin E1 injection on the treatment of chronic severe hepatitis.[J]. Journal of Clinical Hepatology, 2004, 20(2): 89-90. |
[12] | Zhang JianZhen. Compared research serum indexes and pathological changes of liver in hepatology chronic hepatitis B.[J]. Journal of Clinical Hepatology, 2004, 20(3): 153-154. |
[13] | Xie XingRong, Zhan GuoQing, Deng WenQin, Li JinKe. Clinical study on phentolamine-mesilate combined diammonium-glycyrrhizinate in the treatment of chronic hepatitis gravis.[J]. Journal of Clinical Hepatology, 2004, 20(6): 351-352. |
[16] | Zheng RuiDan, Rao RiChun, Lin FuDi, Xu ZhongYu, Zhang YangGen, Zhang MinFeng. Changes of blood lipopoly saccharide activity modulating proteins and its clinical significance in patients with chronic severe viral hepatitis B[J]. Journal of Clinical Hepatology, 2002, 18(4): 212-214. |